PLAINSBORO, N.J. – Wegovy pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity. Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.
"We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. "Wegovy pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what's possible in weight management, and to make that possible, we have worked to ensure Wegovy pill is affordable and accessible to those who need it, however they choose to receive their care."
Wegovy is backed by proven results, as millions have been prescribed Wegovy (semaglutide) injection 2.4 mg for weight management since 2021. Wegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials, boasting an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo. When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy pill compared to about 2% (2.4%) for placebo.
With once-daily oral dosing, Wegovy pill can provide patients with a practical option as part of their daily routine to help people achieve meaningful weight loss.
OASIS 4 Results
| |||
Wegovy® pill 25 mg | Placebo | ||
Percent weight | If all patients stayed on treatment
(Trial product estimand*) | ~17% | ~3% |
Analysis of all patients regardless of if they stayed on treatment
(Treatment policy estimand**) | ~14% | ~2% | |
For Wegovy pill based on baseline body weight of 235 lb., and for placebo based on baseline body weight of 231 lb.
In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.
Novo Nordisk continues to pursue innovative delivery models and strategic collaborations to meet people where they are, reaching more patients in more ways. This is designed to help patients obtain authentic, FDA-approved medicines and avoid potentially unsafe, unapproved alternatives. Wegovy is available through a range of options including US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, NovoCare® Pharmacy, GoodRx and others.
Wegovy pill is available to all eligible patients with multiple affordability options. Self-pay patients can start at around $5/day ($149/month) for the starting dose of 1.5 mg. The 4 mg dose will also be available for $149/month through April 15, 2026, then $199/month after, and the highest doses of Wegovy pill will be available for $299. Commercially insured patients pay as little as $25/month with the Wegovy® savings offer.
Wegovy pill is only approved in the US and will be available in 1.5 mg (starter dose), 4 mg, 9 mg, and 25 mg.
